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The targets for tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and selective norepinephrine
reuptake inhibitors (SNRIs) are known to be the serotonin and norepinephrine transport (reuptake) proteins which are embedded
in presynaptic nerve terminals and function to bring these neurotransmitters from the synaptic cleft back into the presynaptic
neuron. Using a combination of intrinsic and extrinsic ﬂuorescence quenching, Stern-Volmer analysis, and protease protection
assays, we have shown that therapeutics from each of these three classes of antidepressants bind to the extracellular S1S2 domain
of the NR1-1b subunit of the NMDA receptor. These results are in agreement with recent work from our lab demonstrating
the interaction of antidepressants with the S1S2 domain of the GluR2 subunit of the AMPA receptor, another member of the
ionotropic glutamate receptor subfamily, as well as work from other labs, and continue the discussion of the involvement of
ionotropic glutamate receptors in depression.
Copyright © 2008 R. Raabe and L. Gentile. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Ionotropic glutamate receptors (iGluRs) are a family of
ligand-gated ion channels located on the postsynaptic neural
membrane which open in response to extracellular binding
of the neurotransmitter glutamate. These receptors play an
important role in memory, learning, development, and neu-
ral plasticity. As such, their misregulation has been impli-
cated in a number of disease states such as the ischaemic
stroke cascade, schizophrenia, epilepsy, and Alzheimer’s,
Huntington’s, and Parkinson’s Disease.
The functional unit of each member of the iGluR family
(NMDA, AMPA, and kainate receptors) is a tetramer; ho-
motetramer for AMPA and kainate receptors and heterote-
tramer, composed of NR1 (one of eight alternatively spliced
versions) and NR2 subunits (one of four versions encoded
by four diﬀerent genes) for NMDA receptors. Subunits from
any of these family members are modular in nature, con-
taining seven domains: an amino terminal domain (ATD)
important for the interaction between subunits, a nonse-
quential extracellular S1S2 neurotransmitter binding do-
main, three membrane spanning domains, a re-entrant
loop which forms the pore of the ion channel when the
tetramer is assembled, and an intracellular C-terminal tail.
Soluble extracellular GluR2 (AMPA) and NR1-1b (NMDA)
S1S2 domains have been constructed by eliminating all
three transmembrane spanning regions plus the re-entrant
loop and linking the S1 and S2 domains by two amino
acids (GT) [1–4]. These S1S2 domains have been shown to
possess near native binding aﬃnities for both agonists and
antagonists and their structures have been studied by X-ray
crystallography (Figure 1)[ 1–4].
In the past twenty years, there has been an accumu-
lation of data suggesting that iGluRs are also involved in
the mechanism of action of antidepressants. This is a de-
parture from the idea that antidepressants function solely by
either inhibiting monoamine oxidase (MAOIs) or the sero-
tonin or norepinephrine transport proteins (TCAs, SSRIs,
or SNRIs). Data linking iGluRs to antidepressant activi-
ties include experiments demonstrating direct binding of
tricyclic antidepressants to the extracellular S1S2 region
of AMPA receptors [5, 6], open channel block of NMDA
receptors by antidepressants [7, 8], and altered expression
and phosphorylation of AMPA receptors by antidepres-
sants [9, 10]. In addition, AMPA receptor potentiators
and NMDA receptor antagonists have been shown to have
antidepressant-like eﬀects [9, 11–13]. This data has led to the
suggestion that increased activity of AMPA receptors leads to2 Journal of Biophysics
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Figure 1: Crystal structure of the NR1-1b S1S2 domain (PDB code
1PB7) [4] with each of the four tryptophans in blue.
an increase in the expression of brain derived neurotrophic
factor (BDNF), which in turn promotes neurogenesis in the
hippocampus, leading to antidepressant activities [9].
The intrinsic andextrinsic ﬂuorescencestudies presented
here add to the body of knowledge suggesting a role for
NMDA receptors in antidepressant activities. Speciﬁcally,
they demonstrate that ﬁve tricyclic antidepressants (TCAs)
(desipramine, trimipramine, maprotiline, nortriptyline, and
imipramine), four selective serotonin reuptake inhibitors
(SSRIs)(ﬂuvoxamine,paroxetine,sertraline,andﬂuoxetine),
and one selective norepinephrine reuptake inhibitor (SNRI)
(venlafaxine), see Figure 2, bind to the S1S2 domain of the
NR1-1b subunit of the NMDA receptor. The only antide-
pressant that showed no binding in any of our studies, at
concentrations as high as 5.21mM, was the SSRI citalopram.
2.ExperimentalProcedures
2.1. ProteinExpressionand Puriﬁcation of
the NMDA NR1-1b S1S2Domain
The cloning plasmid for the NMDA NR1-1b S1S2 domain,
provided by Eric Gouaux (Oregon Health and Science Uni-
versity), was chemically transformed into E. coli Origami
B(DE3) cells. The expression system was designed as fol-
lows: (His)8-TSG-LVPRG(thrombin cut site)-S1(394-544)-
GT-S2(663-800). Expression and puriﬁcation of NMDA
NR1-1b S1S2 protein were performed as in Furukawa and
Gouaux [4].
2.2. IntrinsicFluorescence
Intrinsic ﬂuorescence studies were performed in a Cary Ec-
lipse ﬂuorometer at 25◦C. All emission scans were acquired
from 300 to 400nm upon excitation at 290nm, with 10nm
excitation and emission slit widths in a 10mm-path-length
cell. Excitation was performed at 290nm to minimize
interference from both tyrosine residues in the NMDA NR1-
1bS1S2domainaswellasthearomaticantidepressantsbeing
studied. Before data acquisition, samples were incubated for
thirty seconds in the sample holder at 25◦C. Analysis of
the buﬀer emission signal showed that it contributed less
than half a percent to the ﬂuorescence intensity of the NR1-
1b S1S2 domain. Thus, data was reported without a buﬀer
subtraction.
Protein samples were at a ﬁnal concentration of 5.29μM
in buﬀer 3 (10mM MES, pH 6.5, 25mM NaCl, 1mM
glycine). All antidepressants were solubilized in 100% meth-
anol to the highest attainable concentrations. To account for
any eﬀects methanol had on ﬂuorescence intensity, protein
spectra with methanol were collected, allowing direct com-
parison between samples with and without antidepressant.
Eachdatasetconsistedofatleastthreeindependentemission
spectra of identically prepared samples. The data is reported
with error determined at the 95% conﬁdence level.
2.3. IntrinsicQuenchingStudies
The ﬂuorescence intensity of the NR1-1b S1S2 domain was
determined in the presence and absence of each antide-
pressant with the appropriate blank subtraction. The ﬁnal
concentrations ofeach TCA-desipramine, imipramine, trim-
ipramine, nortriptyline, and maprotiline were 136.9μM,
136.9μM, 136.9μM, 2.08mM, and 3.18mM, respectively.
The ﬁnal concentrations of each SSRI-paroxetine, citalo-
pram, and sertraline were 3.75mM, 1.88μM, and 1.88mM,
respectively. For all samples, the ﬁnal concentration of
methanol was kept at 1.8%.
2.4. Kd Determination
Antidepressants were added to ﬁnal concentrations as fo-
llows: nortriptyline: 1.24–3.61mM, imipramine or desipr-
amine: 8–570μM, trimipramine: 130–570μM, sertraline:
0.74–1.84mM, ﬂuvoxamine: 0.74–2.37mM. A double recip-
rocal plot was used to determine Kd, which derives from
the Benesi-Hildebrand relationship, provided there is a 1:1
binding stoichiometry. The equation is: 1/ΔF = 1/((F∞−
Fo)·Kd[L])+1/(F∞ −Fo), where Fo is the ﬂuorescence inten-
sity in the absence of ligand, F∞ is the ﬂuorescence intensity
with saturating concentration of ligand, F is the ﬂuorescence
intensity at some particular [ligand], ΔF is (F − Fo), and Kd
is the dissociation constant. When 1/ΔF is plotted against
1/[L], a linear relationship exists. The intercept on the x-axis
is −Kd.[ 14]. Note, this method to determine Kd is based on
the formation of ground state NMDA NR1-1b S1S2 domain:
antidepressant complexes, and could be altered by dynamic
quenching.
2.5. Stern-Volmer Analysis
Acrylamide(Sigma)ranginginﬁnalconcentrationfrom16.3
to 113.9mM was added to 5.29μM NR1-1b S1S2 premixed
with antidepressant (at ﬁnal concentrations as above for
intrinsic quenching studies, with the exception of sertralineJournal of Biophysics 3
O
N
F
NC
N
F3C
O N
H
F3C
N
O
O
2
N
N HN
O
O
N
H
O
F
Cl
Cl
NHCH3 H
H
N
N
OH
N
MeO
HN HN
NH
TCAs
Desipramine Imipramine Nortriptyline Maprotiline
Trimipramine
Fluvoxamine SSRIs Paroxetine
Sertraline Fluoxetine Citalopram
SNRI
Venlafaxine
Figure 2: The TCAs, SSRIs, and SNRIs above, with the exception of citalopram, were found to bind to the NMDA NR1-1b S1S2 domain.
which was at 0.94mM). Plots of (F0/F)−1v e r s u sac ryl a m i d e
concentration were constructed.
2.6. ExtrinsicFluorescence
Extrinsic ﬂuorescence studies were performed in a Cary Ec-
lipse ﬂuorometer at 25◦C. All emission scans were acquired
from 400 to 600nm after excitation at 380nm with 20nm
slit widths for emission and excitation in a 10mm-path-
length cell. Before data acquisition, samples were incubated
for thirty seconds in the sample holder at 25◦C. Blanks
were collected both for the antidepressants and the NR1-
1b S1S2 domain. Three emission spectra of identically pre-
pared samples were averaged for each plot. 8-Anilino-1-
naphthalenesulfonic acid (ANS, TCI America), in a 1:1
molar ratio, was added to 5.29μM of the NR1-1b S1S2
domain premixed with antidepressant (at ﬁnal concentra-
tions as above for intrinsic quenching studies in addition to
the SSRIs ﬂuoxetine (8.62μM) and ﬂuvoxamine (2.81mM)
and the SNRI venlafaxine (29.07μM)). As with all intrinsic
assays, total methanol concentration was kept at 1.8%.
Plots of intensity versus wavelength were constructed from
averaged emission spectra.
2.7. ProteaseProtection
Antidepressants (at ﬁnal concentrations as above for the
extrinsic assays, with the exception of sertraline which was
added to a ﬁnal concentration of 940μM) were added to
60μL aliquots of the NR1-1b S1S2 domain at a ﬁnal concen-
trationof5.29μM.TheNR1-1bS1S2domain/antidepressant
c o m p l e x e sw e r ea l l o w e dt oi n c u b a t eo ni c ef o r5m i n u t e s
before trypsin (Sigma: 13500U/mg) was added to a ﬁnal
concentration of 5.29μM, yielding a 1:1 molar ratio of
protein to trypsin. The reactions were then incubated at
room temperature for 45 minutes. Digestion was stopped
by the addition of sample loading dye, DTT (50mM), and
incubation at 100◦C for 10 minutes. Each reaction was
visualized by 12% SDS-PAGE.
3. Results and Discussion
3.1. IntrinsicTryptophanFluorescence
Demonstrates Bindingof 5 TCAs and
3 SSRIsto the NMDA NR1-1b S1S2 Domain
The environment of the four tryptophan residues in the
NMDA NR1-1b S1S2 domain, W498, W731, W768, W792,
can be monitored by ﬂuorescence spectroscopy. Upon exci-
tation, the emission maximum (λmax) and ﬂuorescence
intensity of a tryptophan residue depends upon the polarity
of its environment. By comparing the emission spectrum
(λmax and ﬂuorescence intensity) of the apo NMDA NR1-
1b S1S2 domain to antidepressant bound complexes, it is
possible to determine if the antidepressant has bound to
the S1S2 domain and caused a change in the environment4 Journal of Biophysics
Table 1: λmax of the NR1-1b S1S2 apo domain and of the NR1-1b
drug bound complexes.
Antidepressant λmax (nm) Standard deviation (nm)
Desipramine 326.77 1.90
Nortriptyline 327.8 0.950
Imipramine 328.04 1.38
Trimipramine 327.27 2.19
Maprotiline 322.04 1.83
Fluvoxamine 328.57 1.91
Paroxetine 328.3 0.960
Sertraline 329.07 0
Apo 326.24 1.54
of the NR1-1b S1S2 tryptophan residues. An increase in
the polarity of the environment surrounding a tryptophan
causes an increase in the λmax of emission and a decrease
in the ﬂuorescence intensity. The data in Figure 3(a),w h i c h
monitors the intensity of the tryptophan emission from
the NMDA NR1-1b S1S2 domain shows binding of the
TCAs desipramine (Kd: 730 ± 150μM; for Kd data see
supplemental Figures 1S and 2S), trimipramine (Kd:1 .09 ±
0.24mM), maprotiline, nortriptyline (Kd:7 .36 ± 2.06mM),
andimipramine (Kd: 830 ±150μM).Thedata inFigure 3(b)
demonstrates the binding of the SSRIs paroxetine, sertraline
(Kd: 240 ± 90μM), and ﬂuvoxamine (Kd:6 .54 ± 3.48mM).
These intrinsic ﬂuorescence studies are complicated by the
fact that paroxetine, sertraline, citalopram, and venlafaxine,
the former two that showed evidence of binding to the NR1-
1b S1S2 domain, and the latter two that did not, all had
relatively high intrinsic ﬂuorescence signals in the emission
range of tryptophan. To compensate for this, lower drug
concentrations had to be used which reduced the range
of workable concentrations, proving problematic for Kd
determination. Low drug solubility in methanol (one of
the only organics compatible with a folded S1S2 domain)
further complicated Kd determination for maprotiline and
sertraline.
Based on this intrinsic ﬂuorescence quenching data, the
only antidepressant which either binds in a unique location
on the S1S2 domain or causes a unique conformational
change upon binding is maprotiline, the binding of which
increases, rather than quenches, the tryptophan ﬂuorescence
emission. The unique mode of binding of maprotiline is
further supported by the shift in the maximum wavelength
of emission of the maprotiline bound S1S2 complex, from
326.24 ± 1.54nm (apo) to 322.04 ± 1.83nm (bound),
Table 1.T h i sd e c r e a s ei nλmax and increase in ﬂuorescence
emission upon binding of maprotiline are consistent with
the tryptophan residues being in a more nonpolar environ-
ment upon complex formation, either due to direct contact
with maprotiline or to a conformational change upon
maprotiline binding that places them in a more nonpolar
portion of the protein.
The only other ligand which caused a statistically sig-
niﬁcant shift in λmax of the S1S2 domain is sertraline,
which upon complex formation is shifted to 329.07 ± 0nm
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Figure 3: Intrinsic ﬂuorescence quenching of the NR1-1b S1S2
domain with (a) TCAs and (b) SSRIs. To 5.29μM NR1-1b S1S2
in buﬀer 3 was added quenchers in the following ﬁnal con-
centrations: (a) TCAs-desipramine, trimipramine, or imipramine:
137μM, maprotiline: 3.18mM, nortriptyline: 2.08mM; (b) SSRIs-
paroxetine: 3.75mM, sertraline: 1.88mM, ﬂuvoxamine: 2.81mM.
(Table 1). This increase in λmax and decrease in ﬂuorescence
emission upon binding of sertraline, the tightest binding
antidepressant used in these studies, are consistent with the
tryptophan residues being in a more polar environment
upon complex formation, either due to direct contact with
sertraline or to a conformational change upon sertraline
binding that places them in a more polar or solvent exposed
portion of the protein.
3.2. ExtrinsicANS Fluorescence Conﬁrms
the Binding of 4 TCAs and3 SSRIsand
Demonstrates Bindingof Fluoxetine(SSRI)
andVenlafaxine(SNRI) to the NMDA
NR1-1b S2S2 Domain
If an antidepressant bound to the S1S2 domain of the NR1-
1b subunit of the NMDA receptor, but did not changeJournal of Biophysics 5
the polarity surrounding the tryptophans or changed them
in such a way that the results canceled each other out,
it would not be possible to determine binding from the
intrinsic ﬂuorescence studies described above. To address
this,theextrinsicﬂuorANSwasusedtoprobeantidepressant
binding. Upon binding to hydrophobic patches on the
surface of proteins, the λmax of ANS decreases and its
emission intensity increases. As can be seen in Figures 4(a)
and 4(b), the emission spectrum of ANS bound to NR1-1b
S1S2 complexes of desipramine, trimipramine, maprotiline,
or nortriptyline was signiﬁcantly diﬀerent from ANS bound
to the apo S1S2 domain, conﬁrming the binding of these
antidepressants. Again, the uniqueness of maprotiline bind-
ing is conﬁrmed by the shift in λmax of the complex. No data
is presented for the ANS bound NR1-1b S1S2-imipramine
complex. In this case, a strong, shifted ﬂuorescence signal
from the ANS, imipramine, buﬀer blank suggested a direct
binding of ANS to imipramine.
The three SSRIs that showed binding by intrinsic ﬂu-
orescence quenching, sertraline, paroxetine, and ﬂuvoxam-
ine, all had spectra that were signiﬁcantly diﬀerent from
the apo spectrum, conﬁrming their binding (Figure 4(d)).
In addition, ANS emission spectra conﬁrmed the binding
of both the SNRI venlafaxine (Figure 4(c)) and the SSRI
ﬂuoxetine (Figure 4(e)), neither of which showed binding
in the intrinsic ﬂuorescence assays. Citalopram is the only
antidepressant studied which showed no evidence of bind-
ingineithertheintrinsicorextrinsicassaysatconcentrations
as high as 5.21mM.
3.3. Stern-Volmer Quenching Analysis
DifferentiatesConformational Changes
ObservedUpon AntidepressantBinding
To probe the conformational change elicited upon binding
of each of the antidepressants, a Stern-Volmer analysis was
performed. In these experiments, the ability of an external
molecule, in this case acrylamide, to quench tryptophan ﬂu-
orescence is monitored in both the apo NR1-1b S1S2 and in
the antidepressant bound NR1-1b S1S2 domains. The Stern-
Volmerconstant,Ksv,deﬁnedastheproductofthebimolecu-
larcollisionalconstant,kq,andthelifetimeofthetryptophan
residues in the absence of quencher, τ0,i sm e a s u r e d .T h e
bimolecular collisional constant is a measure of the accessi-
bility of acrylamide to the tryptophans with an increase in
kq equating to an increase in accessibility to the ﬂuorophore.
If it is assumed that the lifetime of the tryptophans do not
change upon antidepressant binding [15–17], then changes
in Ksv are due to changes in kq and therefore reﬂect
the change in accessibility of the tryptophan residues to
acrylamide upon antidepressant binding. The data in Table 2
shows that upon binding to any of the antidepressants, the
accessibility of the tryptophan residues in the S1S2 domain
to acrylamide increased when compared to the apo protein.
Within the TCA class of antidepressants, the conformational
change upon imipramine/trimipramine binding appears
distinct from that of desipramine/nortriptyline binding,
which appears distinct from maprotiline binding. In these
Table 2: Ksv values for the NMDA NR1-1b S1S2 apo domain and
for the NR1-1b antidepressant complexes.
Antidepressant (family) Ksv (μM−1)E r r o r i n Ksv (μM
−1)
Desipramine (TCA) 2.67 0.10
Nortriptyline (TCA) 2.56 0.17
Imipramine (TCA) 3.15 0.06
Trimipramine (TCA) 3.02 0.21
Maprotiline (TCA) 5.92 0.47
Sertraline (SSRI) 2.23 0.10
Paroxetine (SSRI) 3.06 0.13
Fluvoxamine (SSRI) 3.77 0.07
Apo 1.61 0.11
assays, the binding of imipramine could not be distinguished
from trimipramine, and the binding of desipramine could
not be distinguished from nortriptyline. Within the SSRI
class of antidepressants, all conformational changes elicited
upon binding to the NR1-1b S1S2 domain were found
to alter the accessibility of the tryptophan residues in
statistically signiﬁcant ways.
3.4. ProteaseProtectionAssays Differentiate
Conformational Changes of Nortriptyline
andDesipramineBinding to the NMDA
NR1-1b Domain
To diﬀerentiate the binding of desipramine and nortripty-
line as well as trimipramine and imipramine to the S1S2
domain of the NR1-1b subunit, a limited trypsin digest was
performed on the antidepressant bound complexes. Figure 5
shows that this method was unsuccessful in diﬀerentiating
the conformational changes associated with imipramine
(lane 2) and trimipramine (lane 6) binding. However, it was
successful in diﬀerentiating the conformational changes
associated with nortriptyline (lane 4) and desipramine (lane
1) binding with the conformational change associated with
nortriptyline aﬀording much less protection to proteolysis
than the desipramine bound complex or the apo S1S2 do-
main.
3.5. Summary
A combination of intrinsic and extrinsic ﬂuorescence bind-
ing studies, Stern-Volmer analysis, and protease protection
assays provides evidence for the binding of ﬁve TCAs, four
SSRIs, and one SNRI to the NMDA NR1-1b S1S2 domain.
Data from the SSRI class of antidepressants supports the
hypothesis that the conformational changes elicited upon
bindingtotheS1S2domainareunique.WithintheTCAclass
of antidepressants, the conformational changes of the S1S2
domain upon binding to each drug also appear to be unique,
with the exception of binding to imipramine and trim-
ipramine. Structurally, the diﬀerence between imipramine
and trimipramine (Figure 2) is the branched aliphatic side
chain present in trimipramine. While it is possible that this6 Journal of Biophysics
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Figure 4: ANS binding. To 5.29μM NR1-1b S1S2 in buﬀer 3 was added ANS in a 1:1 molar ratio along with a TCA, SSRI, or SNRI in the
following ﬁnal concentrations: (a) TCAs-desipramine (---): 137μM, trimipramine (···): 137μM, maprotiline (): 3.18mM; (b) TCAs-
nortriptyline (···): 2.08mM; (c) SNRI-venlafaxine (---): 2.76mM; (d) SSRI-ﬂuvoxamine (---): 2.81mM, paroxetine (···): 3.75mM,
sertraline (): 1.88mM; (e) SSRI-ﬂuoxetine (---): 862μM. In all ﬁgures the solid line is the extrinsic ﬂuorescence of ANS:NR1-1b S1S2. In
all ﬁgures, intensities were corrected by subtracting the drug and ANS blank.
additional steric hindrance in trimipramine causes it either
to bind to a unique site or in a unique way to the same site
within the S1S2 domain, it is also possible that these two
drugs have very similar binding to the S1S2 domain of the
NR1-1b subunit. None of the studies performed provide
evidence of binding of this iGluR domain to the SSRI citalo-
pram. Perhaps the presence of the nitrile group, present in
none of the other antidepressants studied, prevents binding
to the NR1-1b S1S2 domain.
Based upon the ways in which iGluRs have been pro-
posed to interact with antidepressants, this direct binding to
theextracellularS1S2domainoftheNMDANR1-1bsubunitJournal of Biophysics 7
12345678
Figure 5: Protease protection assay of NR1-1b S1S2:TCA com-
plexes. To 5.29μM NR1-1b S1S2 in buﬀer 3 was added the
ﬁnal quenching concentrations of TCAs prior to addition of a
1:1 molar ratio of trypsin. The results of the trypsin cuts were
visualized by 12% SDS PAGE. Lanes were loaded as follows,
(1): desipramine-bound, (2): imipramine-bound, (3): apo NR1-
1b S1S2, (4): nortriptyline-bound, (5): maprotiline-bound, (6):
trimipramine-bound, (7): trypsin, (8): uncut NR1-1b S1S2.
may ﬁt into the previously observed category of NMDA
antagonists having antidepressant activities [9, 11–13]. As
the TCAs have been shown to produce open channel block
of the NMDA receptors, however, diﬀerentiating antagonist
eﬀects from external S1S2 binding and open channel block
will be diﬃcult [7, 8]. As is the case for open channel block,
for direct binding of antidepressants to the NMDA NR1-1b
S1S2 domain to play a major role in the mode of action
of these drugs, the diﬀerences in their binding aﬃnities
(Kd range 0.24–7.36mM), and typical therapeutic plasma
concentrations (0.17–1μM), will need to be resolved [7,
8, 18, 19]. Part of this solution may lie in the fact that
while these isolated iGluR S1S2 domains have been shown
to possess near native binding aﬃnities for both agonists
and antagonists in vitro, their in vivo interactions with
antidepressants could be quite diﬀerent [1–3, 20–22].
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